pd

Anti-Mouse PD-1 Antibody (RMP1-14) is an IgG2a antibody inhibitor against mouse PD-1 and can block PD-1/PD-L1 signaling.

Anti-Mouse PD-L1 Antibody (10F.9G2) is an IgG-class antibody against mouse PD-L1.

PD-1 PD-L1-IN-20 is a small molecule inhibitor of PD-1 PD-L1 protein-protein interaction, blocking the interaction with an IC50 of 5.29 nM. PD-1 PD-L1-IN-20 can be used to study cancer, infectious diseases, and autoimmune diseases.

Human membrane-bound PD-L1 polypeptide serves as an antigen for inducing the production of PD-L1 antibodies [1].

PD-360324 is a human monoclonal antibody (mAb) that targets CSF1/M-CSF. It can be utilized in research related to skin lupus, pulmonary sarcoidosis, and rheumatoid arthritis.

Anti-PD-L1/B7-H1 Antibody (29E.2A3) represents a chimeric antibody of mouse IgG2b, κ type, specifically targeting human PD-L1/B7-H1. The recommended isotype control for this antibody is Mouse IgG2b kappa, Isotype Control.

Anti-MousePD-1Antibody (J43) is an IgG antibody derived from mice, targeting PD-1 and originating from American hamsters. The isotype control for Anti-MousePD-1Antibody (J43) is Armenian hamsterIgG, Isotype Control.

The Anti-MousePD-1Antibody (29F.1A12) is an antibody derived from rat IgG2akappa that targets PD-1 in mice. The isotype control for Anti-MousePD-1Antibody (29F.1A12) is RatIgG2akappa, Isotype Control.

The Anti-Mouse PD-L1/B7-H1 Antibody (10F.2H11) is a rat IgG2b kappa mouse antibody specifically targeting PD-L1/B7-H1. The recommended isotype control for this antibody is Rat IgG2b kappa, Isotype Control.

Anti-MousePD-1Antibody (S-5001) is an IgG1 antibody inhibitor that targets mouse PD-1.

Anti-Mouse/Rat/HumanPD-L1Antibody (368A.4H1) is a murine-derived IgG1, κ antibody inhibitor targeting PD-L1 in mice, rats, and humans.

Anti-Mouse/Human phosphorylated PD-1/CD279 Antibody (407.6G12) is an IgG2a, κ antibody inhibitor derived from mice, targeting phosphorylated PD-1/CD279 in both mice and humans.

Anti-PD-L1 Blocking Antibody (5I615) is a Rabbit IgG monoclonal antibody targeting Human PD-L1 Blocking.

Anti-PD-1 Antibody (8P789) is a mouse (varialbe region) / human (kappa / IgG1 constant) chimeric monoclonal antibody targeting Human PD-1.

Anti-MousePD-1(LALA-PG) Antibody (RMP1-14) is an IgG2a, κ antibody inhibitor derived from mice that targets and inhibits mouse PD-1.

Anti-Mouse PD-1 Antibody (D265A) is an IgG2a, κ antibody inhibitor derived from mice, specifically targeting mouse PD-1.

Anti-CCL2 (Carlumab)-SPDB-DM4 is an antibody-drug conjugate (ADC) composed of the human-derived anti-CCL2 (chemokine ligand 2) antibody Carlumab, linked to the microtubule inhibitor DM4 via the SPDB linker. The toxic component and linker of the ADC are sulfo-SPDB-DM4. This compound is utilized in cancer research.

Anti-SLC34A2 (Lifastuzumab)-SPDB-DM4 is an antibody-drug conjugate (ADC) composed of the humanized anti-SLC34A2 (sodium-dependent phosphate transporter 2) antibody, Lifastuzumab, linked via SPDB to the tubulin inhibitor DM4. The toxic component and linker of this ADC is sulfo-SPDB-DM4. This compound can be utilized for cancer research.

Atezolizumab is an antibody inhibitor, a humanized monoclonal antibody, IgG1, which targets PD-L1 and blocks the interaction of PD-L1 with PD-1. Atezolizumab has antitumor activity and promotes T-cells to attack tumor cells.

Avelumab, a fully human IgG1 anti-PD-L1 monoclonal antibody, exhibits potential antibody-dependent cell-mediated cytotoxicity.

Nivolumab is a monoclonal antibody, a humanized IgG4 antibody to PD-1. Nivolumab has antitumor activity and is used in the treatment of melanoma, non-small cell lung cancer, renal cell carcinoma and others.

Pembrolizumab (MK-3475) is a highly selective humanized monoclonal antibody that antagonizes PD-1. It can block the PD-1 protein on T cells and prevent their interaction with PD-L1 on cancer cells.

Durvalumab (MEDI 4736) is a humanized monoclonal antibody targeting PD-L1. It can block the interaction of PD-L1 with PD-1 and CD80, with IC50 values of 0.1 and 0.04 nM, respectively. Durvalumab is often used in combination with platinum-based compounds for the treatment of non-small cell lung cancer and advanced hepatocellular carcinoma cells.

Tiragolumab(MTIG-7192A) is a monoclonal antibody that targets T-cell immunoglobulin and the ITIM structural domain (TIGIT).Tiragolumab is often used in combination with the PD-L1 inhibitor, Atezolizumab, for the treatment of solid malignant tumors such as non-small cell lung cancer.